Related Experiment Video
Updated: Jun 11, 2026
09:57
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
Is MRD eradication a desirable goal in CLL?
Carol Moreno1, Matthias Ritgen, Andy Rawstron
1Haematology Department, Institute of Haematology and Oncology, Hospital Clínic, University of Barcelona, Spain. camoreno@clinic.ub.es
Best Practice & Research. Clinical Haematology
|July 13, 2010
Summary
Minimal residual disease (MRD) status is a key prognostic factor for chronic lymphocytic leukemia (CLL) patients. Achieving MRD-negative status indicates a better prognosis, but its use as a therapeutic goal requires further research.
Area of Science:
- Hematology
- Oncology
- Clinical Research
Background:
- Therapy response is the most critical prognostic indicator for chronic lymphocytic leukemia (CLL) patients requiring treatment.
- Achieving minimal residual disease (MRD)-negative status correlates with improved prognosis compared to other response levels.
- Standardized methods, including allele-specific polymerase chain reaction (PCR) and four-colour cytofluorometry, exist for MRD assessment in CLL.
Purpose of the Study:
- To discuss the prognostic significance of minimal residual disease (MRD) status in chronic lymphocytic leukemia (CLL).
- To highlight the need for further investigation into the benefits of achieving MRD-negative status in CLL patients.
- To emphasize the importance of stratifying patients by clinical and biological parameters in future CLL trials.
Main Methods:
- Review of current understanding of prognostic factors in chronic lymphocytic leukemia (CLL).
- Discussion of established methods for minimal residual disease (MRD) assessment.
- Analysis of the implications of MRD status on patient outcomes.
Main Results:
- Minimal residual disease (MRD)-negative status is associated with a better prognosis in chronic lymphocytic leukemia (CLL) patients.
- Current evidence suggests MRD status should not be a treatment goal outside of clinical trials.
- Standardized MRD detection methods are available for CLL.
Conclusions:
- While MRD-negative status is a favorable prognostic marker in CLL, its role as a direct therapeutic target needs validation.
- Large, controlled clinical trials are necessary to confirm the benefits of achieving MRD-negative status.
- Future CLL trials should incorporate comprehensive patient stratification based on clinical and biological factors alongside MRD status.
